{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:38:51Z","timestamp":1790667531178,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to compare tumor lesion detectability and diagnostic accuracy of whole-body magnetic resonance imaging (WB-MRI) and radioiodine-labeled meta-iodo-benzylguanidine (<jats:italic>m<\/jats:italic>IBG) imaging techniques in patients with metastatic pheochromocytoma and paraganglioma (PPGL). This retrospective study included 13 patients had pheochromocytoma and 5 had paraganglioma, who were all suspected of having metastatic tumors. Each patient underwent WB-MRI and <jats:sup>123<\/jats:sup>I-<jats:italic>m<\/jats:italic>IBG as a pretreatment screening for <jats:sup>131<\/jats:sup>I-<jats:italic>m<\/jats:italic>IBG therapy. Two expert reviewers evaluated WB-MRI, <jats:sup>123<\/jats:sup>I-<jats:italic>m<\/jats:italic>IBG images, and post-therapy <jats:sup>131<\/jats:sup>I-<jats:italic>m<\/jats:italic>IBG images for the presence of metastatic lesions in the lungs, bones, liver, lymph nodes, and other organs. Diagnostic measures for detecting metastatic lesions, including sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), and receiver operating characteristics (ROC)\u2014area under the curve (AUC), were calculated for each imaging technique. We analyzed WB-MRI images for detecting metastatic lesions, which demonstrated sensitivity, specificity, accuracy, PPV, NPV, and AUC of 82%, 97%, 90%, 96%, 86%, and 0.92, respectively. These values were 83%, 95%, 89%, 94%, 86%, and 0.90 in <jats:sup>123<\/jats:sup>I-<jats:italic>m<\/jats:italic>IBG images and 85%, 92%, 89%, 91%, 87%, and 0.91 in post-therapy <jats:sup>131<\/jats:sup>I-<jats:italic>m<\/jats:italic>IBG images, respectively. Our results reveal the comparable diagnostic accuracy of WB-MRI to one of the <jats:italic>m<\/jats:italic>IBG images.<\/jats:p>","DOI":"10.1038\/s41598-024-64607-2","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T08:02:39Z","timestamp":1718438559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluating the diagnostic efficacy of whole-body MRI versus 123I-mIBG\/131I-mIBG imaging in metastatic pheochromocytoma and paraganglioma"],"prefix":"10.1038","volume":"14","author":[{"given":"Hiroshi","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomo","family":"Hiromasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Kinuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"issue":"2","key":"64607_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3803\/EnM.2017.32.2.152","volume":"32","author":"JWM Lenders","year":"2017","unstructured":"Lenders, J. W. M. & Eisenhofer, G. Update on modern management of pheochromocytoma and paraganglioma. Endocrinol. Metab. 32(2), 152\u2013161 (2017).","journal-title":"Endocrinol. Metab."},{"issue":"9","key":"64607_CR2","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.2967\/jnumed.108.058701","volume":"50","author":"GA Wiseman","year":"2009","unstructured":"Wiseman, G. A. et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: Results from a prospective multicenter trial. J. Nucl. Med. 50(9), 1448\u20131454 (2009).","journal-title":"J. Nucl. Med."},{"issue":"1","key":"64607_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/RLU.0b013e3181feeb5e","volume":"36","author":"M Fukuoka","year":"2011","unstructured":"Fukuoka, M. et al. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT\/CT over planar image in patients with malignant pheochromocytoma\/paraganglioma and neuroblastoma. Clin. Nucl. Med. 36(1), 1\u20137 (2011).","journal-title":"Clin. Nucl. Med."},{"issue":"4","key":"64607_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00467-018-4181-2","volume":"35","author":"A Jain","year":"2020","unstructured":"Jain, A., Baracco, R. & Kapur, G. Pheochromocytoma and paraganglioma\u2014An update on diagnosis, evaluation, and management. Pediatr. Nephrol. 35(4), 581\u2013594 (2020).","journal-title":"Pediatr. Nephrol."},{"issue":"7","key":"64607_CR5","first-page":"1164","volume":"15","author":"P Summers","year":"2021","unstructured":"Summers, P. et al. Whole-body magnetic resonance imaging: Technique, guidelines and key applications. Ecancermedicalscience 15(7), 1164 (2021).","journal-title":"Ecancermedicalscience"},{"issue":"6","key":"64607_CR6","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JWM Lenders","year":"2014","unstructured":"Lenders, J. W. M. et al. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(6), 1915\u20131942 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"64607_CR7","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1148\/rg.2019180130","volume":"39","author":"RV Gottumukkala","year":"2019","unstructured":"Gottumukkala, R. V., Gee, M. S., Hampilos, P. J. & Greer, M. C. Current and emerging roles of whole-body MRI in evaluation of pediatric cancer patients. Radiographics 39(2), 516\u201334 (2019).","journal-title":"Radiographics"},{"issue":"4","key":"64607_CR8","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.2214\/AJR.19.22399","volume":"215","author":"AD Grasparil","year":"2020","unstructured":"Grasparil, A. D. et al. Whole-body MRI surveillance of cancer predisposition syndromes: Current best practice guidelines for use, performance, and interpretation. Am. J. Roentgenol. 215(4), 1002\u20131011 (2020).","journal-title":"Am. J. Roentgenol."},{"issue":"3","key":"64607_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 48(3), 452\u2013458 (2013).","journal-title":"Bone Marrow Transplant."},{"key":"64607_CR10","doi-asserted-by":"publisher","first-page":"20170664","DOI":"10.1259\/bjr.20170664","volume":"91","author":"V Pasoglou","year":"2018","unstructured":"Pasoglou, V. et al. The role of imaging in screening special feature: Review article whole body MRI and oncology: Recent major advances. Br. J. Radiol. 91, 20170664 (2018).","journal-title":"Br. J. Radiol."},{"issue":"12","key":"64607_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/01.rli.0000185878.61270.b0","volume":"40","author":"GP Schmidt","year":"2005","unstructured":"Schmidt, G. P. et al. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: Experience on a 32-channel system. Investig. Radiol. 40(12), 743\u2013753 (2005).","journal-title":"Investig. Radiol."},{"issue":"5","key":"64607_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12149-008-0128-1","volume":"22","author":"A Takano","year":"2008","unstructured":"Takano, A. et al. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: Comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy. Ann. Nucl. Med. 22(5), 395\u2013401 (2008).","journal-title":"Ann. Nucl. Med."},{"issue":"12","key":"64607_CR13","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1007\/s00330-013-2968-x","volume":"23","author":"G Petralia","year":"2013","unstructured":"Petralia, G. et al. Whole-body diffusion-weighted imaging: Is it all we need for detecting metastases in melanoma patients? Eur. Radiol. 23(12), 3466\u20133476 (2013).","journal-title":"Eur. Radiol."},{"issue":"1","key":"64607_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1148\/radiol.2015150489","volume":"278","author":"NS Burris","year":"2016","unstructured":"Burris, N. S. et al. Detection of small pulmonary nodules with ultrashort echo time sequences in oncology patients by using a PET\/MR system. Radiology 278(1), 239\u2013246 (2016).","journal-title":"Radiology"},{"issue":"11","key":"64607_CR15","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1097\/MNM.0b013e3283570ffe","volume":"33","author":"J Yang","year":"2012","unstructured":"Yang, J. et al. I-131 MIBG post-therapy scan is more sensitive than I-123 MIBG pretherapy scan in the evaluation of metastatic neuroblastoma. Nucl. Med. Commun. 33(11), 1134\u20131137 (2012).","journal-title":"Nucl. Med. Commun."},{"issue":"5","key":"64607_CR16","doi-asserted-by":"publisher","first-page":"e1937","DOI":"10.1210\/clinem\/dgaa982","volume":"106","author":"D Granberg","year":"2021","unstructured":"Granberg, D., Juhlin, C. C. & Falhammar, H. Metastatic pheochromocytomas and abdominal paragangliomas. J. Clin. Endocrinol. Metab. 106(5), e1937\u2013e1952 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"64607_CR17","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.2967\/jnumed.107.047738","volume":"49","author":"KP Koopmans","year":"2008","unstructured":"Koopmans, K. P. et al. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J. Nucl. Med. 49, 1232\u20131237 (2008).","journal-title":"J. Nucl. Med."},{"issue":"12","key":"64607_CR18","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1210\/jc.2009-1248","volume":"94","author":"HJ Timmers","year":"2009","unstructured":"Timmers, H. J. et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 94(12), 4757\u20134767 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"64607_CR19","first-page":"217","volume":"43","author":"JC Sisson","year":"1999","unstructured":"Sisson, J. C. & Shulkin, B. L. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q. J. Nucl. Med. 43(3), 217\u2013223 (1999).","journal-title":"Q. J. Nucl. Med."},{"issue":"3","key":"64607_CR20","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1148\/radiology.199.3.8637999","volume":"199","author":"BL Shulkin","year":"1996","unstructured":"Shulkin, B. L. et al. Neuroblastoma: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 199(3), 743\u2013750 (1996).","journal-title":"Radiology"},{"issue":"2","key":"64607_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1148\/radiol.2222010622","volume":"222","author":"S Hoegerle","year":"2002","unstructured":"Hoegerle, S. et al. Pheochromocytomas: Detection with 18F DOPA whole body PET\u2014Initial results. Radiology 222(2), 507\u2013512. https:\/\/doi.org\/10.1148\/radiol.2222010622 (2002).","journal-title":"Radiology"},{"issue":"7","key":"64607_CR22","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s00259-012-2087-y","volume":"39","author":"G Treglia","year":"2012","unstructured":"Treglia, G. et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: A meta-analysis. Eur. J. Nucl. Med. Mol. Imaging 39(7), 1144\u20131153 (2012).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"64607_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s12149-017-1162-7","volume":"31","author":"AS Kroiss","year":"2017","unstructured":"Kroiss, A. S. et al. Compared to 123I-MIBG SPECT\/CT, 18F-DOPA PET\/CT provides accurate tumor extent in patients with extra-adrenal paraganglioma. Ann. Nucl. Med. 31(5), 357\u2013365 (2017).","journal-title":"Ann. Nucl. Med."},{"issue":"10","key":"64607_CR24","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","volume":"43","author":"I Janssen","year":"2016","unstructured":"Janssen, I. et al. PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur. J. Nucl. Med. Mol. Imaging 43(10), 1784\u20131791 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"64607_CR25","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1007\/s00259-022-06064-5","volume":"50","author":"DPD Suurd","year":"2023","unstructured":"Suurd, D. P. D. et al. [18F]mFBG PET\/CT imaging outperforms MRI and [68 Ga]Ga-DOTA-TOC PET\/CT in identifying recurrence pheochromocytoma. Eur. J. Nucl. Med. Mol. Imaging 50(5), 1538\u20131540 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"64607_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/RLU.0000000000004447","volume":"48","author":"P Wang","year":"2023","unstructured":"Wang, P. et al. 18 F-MFBG PET\/CT is an effective alternative of 68 Ga-DOTATATE PET\/CT in the evaluation of metastatic pheochromocytoma and paraganglioma. Clin. Nucl. Med. 48(1), 43\u201348 (2023).","journal-title":"Clin. Nucl. Med."}],"updated-by":[{"DOI":"10.1038\/s41598-024-68300-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64607-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64607-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64607-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T11:09:45Z","timestamp":1722942585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64607-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["64607"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-64607-2","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-024-68300-2","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"24 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-024-68300-2","URL":"https:\/\/doi.org\/10.1038\/s41598-024-68300-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13828"}}